Reactive oxygen species are highly reactive molecules and have been implicated in the pathophysiology of many diseases, including diabetes mellitus, cancer, rheumatoid arthritis, and cardiovascular, renal, inflammatory, infectious, and neurologic diseases (1, 2 ). Cells and biological fluids have an array of protective antioxidant mechanisms, both for preventing the production of free radicals and for repairing oxidative damage (3 ). These antioxidant systems include enzymes, macromolecules, and small molecules, including ascorbic acid, ␣-tocopherol, ␤-carotene, ubiquinol-10, reduced lipoic acid (DHLA), reduced glutathione (GSH), methionine, uric acid, bilirubin, and some amino acids. Antioxidants within cells, cell membranes, and extracellular fluids can be up-regulated and mobilized to neutralize excessive and inappropriate formation of reactive oxygen species, but a deficiency of antioxidant defense may lead to a situation of increased oxidative stress.
Reactive oxygen species are highly reactive molecules and have been implicated in the pathophysiology of many diseases, including diabetes mellitus, cancer, rheumatoid arthritis, and cardiovascular, renal, inflammatory, infectious, and neurologic diseases (1, 2 ) . Cells and biological fluids have an array of protective antioxidant mechanisms, both for preventing the production of free radicals and for repairing oxidative damage (3 ) . These antioxidant systems include enzymes, macromolecules, and small molecules, including ascorbic acid, ␣-tocopherol, ␤-carotene, ubiquinol-10, reduced lipoic acid (DHLA), reduced glutathione (GSH), methionine, uric acid, bilirubin, and some amino acids. Antioxidants within cells, cell membranes, and extracellular fluids can be up-regulated and mobilized to neutralize excessive and inappropriate formation of reactive oxygen species, but a deficiency of antioxidant defense may lead to a situation of increased oxidative stress.
Assays that measure the combined antioxidant effect of the nonenzymatic defenses in biological fluids may be useful in providing an index of ability to resist oxidative damage. Several methods (4 -6 ) have been developed to assess the total antioxidant capacity of human serum or plasma because of the difficulty in measuring each antioxidant component separately and the interactions among different antioxidant components in the serum or plasma. However, the measured antioxidant capacity of a sample depends on which technology and which free radical generator or oxidant is used in the measurement. The ferric reducing ability of plasma (FRAP) assay uses an easily reduced oxidant in a redox-linked colorimetric method (6 ) . Because the redox potential of the ferrous/ ferric couple is 0.77 V, any substance or antioxidant with a redox potential Ͻ0.77 V will drive the ferric reduction, assuming stability of redox product. According to a study by Cao and Prior (7 ) , the FRAP assay does not measure serum proteins and excludes the low-molecular-weight SH-group-containing antioxidants, such as GSH, DHLA, and some amino acids. We developed a novel method for measuring the ubiquinone-9-reducing ability of plasma (URAP). This new method estimates antioxidant systems with redox potentials Յ0.1 V, which will drive the reduction of ubiquinone-9 (Fig. 1A) .
HPLC analysis was performed with an ESA Model 582 Solvent Delivery Module, AS1000 autosampler (Thermo Separation Products), and a reversed-phase Microsorb-MV column [150 ϫ 4.6 mm (i.d.); 5-m bead size] from Rainin. The mobile phase consisted of a mixture of anhydrous sodium acetate (4.2 g; Sigma), 15 mL of glacial acetic acid (Mallinckrodt), 15 mL of 2-propanol (Mallinckrodt), 720 mL of methanol (Fisher), and 250 mL of hexane (Fisher). The flow rate was 1.1 mL/min. The electrochemical detector with ESA Model 5200A CouloChem II has been described previously (8 ) . The electrochemical cells were a postcolumn guard cell and analytical cell containing dual electrodes in series. The potential of the postcolumn guard cell was set at ϩ0.9 V to oxidize any electrochemically active compounds. The first electrode potential of the analytical cell was set at Ϫ0.9 V to transform ubiquinone-9 to ubiquinol-9, and the second electrode was set at ϩ0.35 V with a sensitivity of 1 A for monitoring ubiquinol-9. The concentrations of ubiquinol-9 and ubiquinone-9 were determined simultaneously. Analyses were performed at ambient temperature (ϳ25°C). Systat ® software, Ver. 10 (SPSS), was used for statistical analyses. Results are expressed as the mean (SD) unless noted otherwise. P Ͻ0.05 was considered significant.
Coenzymes Q1, Q2, Q4, Q6, Q7, Q9, and Q10 were purchased from Sigma. Ubiquinol-9 was prepared from ubiquinone-9 by use of sodium borohydride, as described previously (9 ) . Ubiquinol-9 and ubiquinone-9 calibrators in the range 0 -20 mol/L were used to prepare calibration curves in plasma. The linear regression equations for peak height (y; in arbitrary units) and concentration (mol/L) of the injected calibrator (x) were as follows: y ϭ 4.577 ϫ 10 Ϫ6 x Ϫ 0.002 (r ϭ 0.999) for ubiquinol-9 and y ϭ 7.677 ϫ 10 Ϫ6 x Ϫ 0.002 (r ϭ 0.999) for ubiquinone-9. To estimate the limit of detection of the method for ubiquinol-9, we treated a plasma sample (100 L) with a basal ubiquinol-9 concentration of 25 nmol/L with 1-propanol (700 L). Injection of a 100-L aliquot of this plasma extract, corresponding to 0.3 pmol of ubiquinol-9, yielded a ubiquinol-9 peak with a signal-to-noise ratio of 4:1. The experiment was performed in quadruplicate, and the impression (CV) was 14%.
Blood was collected into a Vacutainer TM Tube (Becton Dickinson) containing heparin as anticoagulant and mixed by gentle inversion five to six times. The Vacutainer Tube was not opened to ambient air and was placed on ice or kept refrigerated until processing. Blood was processed within 4 h of collection and centrifuged at 2000g for 10 min at 4°C. Plasma was collected, placed in a capped polypropylene tube, and immediately stored without addition of argon or nitrogen at or below Ϫ70°C until analysis. Plasma samples were obtained from 30 healthy individuals [17 women and 13 men; mean (SD) age, 40 (10) years]. All plasma samples were stored at Ϫ70°C, and analyzed within 1 week. Thawed plasma (100 L) was vortex-mixed with 1-propanol (600 L) and ubiquinone-9 solution (100 L) at ambient temperature for 1 min and centrifuged for 10 min at 5600g. The supernatant layer was transferred to an autosampler vial, and the first portion of the extract (100 L) was injected directly into the HPLC system. The second portion of extract in the same vial was injected after storage for a certain time interval. Sample preparation and HPLC analyses were performed at ambient temperature.
When the test was performed with plasma but with no
Abstracts of Oak Ridge Posters ubiquinone-9 added to the reaction mixture, the HPLC chromatogram showed three peaks, including ubiquinol-9, ubiquinol-10, and ubiquinone-10. Ubiquinone-9 was not detectable, whereas the concentration of ubiquinol-9 was ϳ2% of the total concentrations of ubiquinol-10 (ϳ1 mol/L) and ubiquinone-10 (ϳ0.1 mol/L). No change of ubiquinol-9 was observed over 4 h at room temperature.
To obtain the optimum concentration for plasma reducing power, we studied three concentrations of ubiquinone-9 (2.5, 5, and 7.5 mol/L). Plasma (200 L) was vortex-mixed with 1-propanol (1200 L) and ubiquinone-9 solution (200 L) at ambient temperature for 1 min and centrifuged for 10 min at 10 000 rpm. The supernatant layer was transferred to a vial, and the first portion of the extract (100 L) was injected directly into the HPLC system. Portions of extract in the same vial were injected repeatedly after storage for certain time intervals. Linear responses over a time period up to 5 h were observed for three concentrations of ubiquinone-9 tested. Results indicated that the 0-to 240-min reaction time was suitable for the measurement of URAP. A reaction time of ϳ35 min between two injections was used in the program. The dose-response characteristics of ubiquinone-9 toward plasma showed that the activity is concentration dependent. A ubiquinone-9 concentration of 7.5-mol/L is recommended for use. Coenzymes Q1, Q2, Q4, Q6, and Q7 have also shown activities similar to that of coenzyme Q9; they are therefore potential candidates for measuring plasma reducing power. Ubiquinone-9 was chosen for the current method because reduced and oxidized coenzymes Q9 and Q10 can be measured simultaneously in a single and short HPLC run (8 min) . The representative chromatograms from the analysis of plasma in Fig. 1B were obtained from the same plasma reaction mixture at time 1 (t1) and time 2 (t2), respectively. Reduced and oxidized coenzymes Q9 and Q10 were measured in the same HPLC run. The retention times for ubiquinol-9, ubiquinol-10, ubiquinone-9, and ubiquinone-10 were 3.6, 4.2, 5.5, and 6.8 min, respectively. The increase in the ubiquinol-9 peak after a 35-min reaction time was accompanied by a decrease in the ubiquinone-9 peak, indicating that the increased amount of ubiquinol-9 was attributable to the reduction of ubiquinone-9. Calculation of the ubiquinol-9 production rate (nmol ⅐ L Ϫ1 ⅐ h Ϫ1 ) was based on the increment of ubiquinol-9 concentration between t1 and t2.
The URAP assay gives reproducible results: within-run imprecision for a single sample was 6.5% (n ϭ 6); between-run imprecision for 5 days was 8% (n ϭ 10). The calculated activities of the various antioxidant added to plasma are given in Table 1 . Addition of ␣-tocopherol (25 mol/L), Trolox (25 mol/L), ascorbic acid (100 mol/ L), and uric acid (250 mol/L) decreased the plasma reducing power by 25-44%, whereas addition of DHLA (12.5 mol/L) and ubiquinol-10 (1.25 mol/L) enhanced the reducing power of plasma. The dose-responses of ubiquinol-10 and DHLA were linear, showing that activity is concentration-dependent. DHLA is an antioxidant the concentration of which is low in human plasma. However, the functional part of DHLA as an antioxidant is the SH group, which is also present in nonprotein antioxidants such as GSH and some amino acids. DHLA was therefore used here to represent the SH-group-containing nonprotein compounds. Dose-responses were linear for DHLA and ubiquinol-10 within the concentration range 0 -50 mol/L. The reducing activity did not exist for bilirubin and albumin, because their redox half-reaction potentials are more positive than 0.1 V.
The mean (SD) ubiquinone-9 reduction rate in 30 healthy individuals was 94. 8 (23.8) nmol ⅐ L Ϫ1 ⅐ h Ϫ1 ; after 28 days of storage at Ϫ70°C, repeated analysis of some specimens showed that the URAP values (n ϭ 12) were not significantly different from the values of fresh specimens. No correlation study between the current method and other assays, such as oxygen radical absorbance capacity, FRAP, and trolox equivalent antioxidant capacity, was attempted because these assays use different technologies. The current method is sensitive and specific and can be used to detect the first-line antioxidant system. Clinical studies comparing different population groups, measuring changes in URAP values associated with particular pathologic states, and monitoring URAP values during various treatment strategies are now needed.
There have been many reports describing the combination of immunoassay techniques and nucleic acid amplification using antibodies labeled directly with nucleic acids (the "direct" immuno-PCR approach) (1) (2) (3) . The rationale behind immuno-PCR is to develop ultrahigh-sensitivity labels by exploiting the extremely high productivity of Although the principle of immuno-PCR has been demonstrated in various research applications, there are continuing concerns over both the technical difficulty of linking nucleic acids directly to antibodies (or "adapter" proteins such as streptavidin) and the substantial backgrounds that can be generated by nonspecific binding of the nucleic acid-antibody conjugates to solid phases (2, 4 ) .
We have developed an alternative approach based on an "indirect" immuno-PCR technique that links ELISA techniques and PCR. Because this approach works in a completely different way to traditional immuno-PCR, it may circumvent some of the problems associated with the traditional approach. Here we present the proof of principle of our new approach.
We used a double stranded 5Ј-phosphorylated DNA (dsDNA) substrate for alkaline phosphatase (AP). Shown in Fig. 1A is a schematic of the principle of the enzyme assay method. The procedure takes advantage of the substrate specificity of exonuclease for the 5Ј-phosphorylated form of dsDNA (5 ) . In an immunometric assay, the AP in the antibody conjugate will remove the 5Ј phosphate groups, and the DNA is not then degraded by subsequent exonuclease treatment. PCR, or any other dsDNA amplification technique, can then be used to amplify and detect this nondegraded, "protected" dsDNA. In the absence of AP, the DNA is not protected from the exonuclease, is degraded, and therefore is not detected by PCR. Thus, in an ELISA format, protection of the dsDNA and PCR amplification/detection are indicative of the presence of antibody-AP conjugate bound to captured antigen.
Because each molecule of phosphatase will generate many molecules of detectable dsDNA product, which subsequently enter the PCR process, this indirect immuno-PCR method has effectively two amplification steps, thus giving an increased signal over that of standard direct immuno-PCR.
To prove the principle and assess the sensitivity of our approach for detection of AP, we assayed serial dilutions of unconjugated AP by our method. A 285-bp 5Ј-phosphorylated dsDNA substrate for the enzyme was first generated from the pUC19 (New England Biolabs) DNA template by a standard PCR process with the 5Ј-phosphorylated primers (MWG Biotech) PS1 (5Ј-P-GGC-GAAAGGGGGATGTGCTGCAAGG-3Ј) and PAS1 (5Ј-P-GTGAGCGCAACGCAATTAATGTGAG-3Ј) and Taq (A), principle of the indirect immuno-PCR assay. In the absence of AP, the exonuclease ( exo) recognizes the 5Ј-phosphate groups (P) on the dsDNA and degrades each strand in the 5Ј to 3Ј direction. In a subsequent PCR amplification, with primers that are specific for this dsDNA sequence, the degraded DNA sequence will not generate any PCR product (left side). In the presence of AP, the phosphate groups on the 5Ј end of the dsDNA are removed by the enzyme, and the dsDNA is no longer recognized by the exonuclease. This serves to protect the dephosphorylated dsDNA from degradation. The nondegraded dephosphorylated dsDNA sequence is a template for PCR and will generate the diagnostic PCR product (right side). dNTPs, deoxynucleotide triphosphates. (B), Detection of free AP. The indirect immuno-PCR protocol was performed with serial dilutions of AP (Units shown above gel). PCR products were separated by gel electrophoresis and visualized by ethidium bromide staining. Lanes 0 (no AP) give an indication of the background signal in the assay (the most likely source of which is nonphosphorylated DNA in the 5Ј phosphorylated dsDNA enzyme substrate).
Clinical Chemistry 50, No. 10, 2004 polymerase supplied by Qiagen Ltd. We have previously found that the method can be adversely affected by the quality of the DNA substrate used; any nonphosphoryled DNA that contaminates the phosphorylated DNA substrate in the assay cannot be degraded by the exonuclease and will generate a signal even in the absence of AP. To reduce this signal, or "noise", several steps were taken to ensure that the DNA substrate was highly phosphorylated, and therefore degradable by the exonuclease, before use: the DNA substrate was prepared with polyacrylamide-gel-purified oligonucleotide primers to ensure that the primers used to prepare the substrate were highly phosphorylated; and after PCR, the DNA substrate was agarose-gel-purified and treated with T4 polynucleotide kinase (New England Biolabs). These measures decreased the background of noise in the assay, and enabled us to detect AP activity with high sensitivity.
Serial 10-fold dilutions of calf intestinal AP (New England Biolabs) were prepared and incubated with the phosphorylated dsDNA substrate (final concentration in the reaction of 1 ng/L) for 1 h at 37°C in Buffer 3 (from the enzyme supplier). We then added 0.5 U of exonuclease (New England Biolabs), and continued the incubation for 1 h. We then amplified 5L of each reaction mixture in a standard "detection" PCR process using the PS1 and PAS1 primers. The amplification was carried out with an initial denaturation step at 94°C for 5 min and subsequently 25 thermal cycles of the following profile: 94°C for 30 s, 62°C for 30 s, and 72°C for 30 s.
Shown in Fig. 1B are the PCR products from the detection step, separated by agarose gel electrophoresis and stained with ethidium bromide. Visual inspection showed that even with our steps to ensure that the DNA substrate was highly phosphorylated, some molecules could not be degraded by the exonuclease and even in the absence of AP generated a background signal or noise. However, the signal generated by dilutions of AP were significantly greater than this background noise and enabled us to detect as few as 10 Ϫ11 U of AP, which is approximately equivalent to 10 ϫ 10 Ϫ18 g, or as few as 60 molecules of AP in our assay. This visual interpretation was confirmed by quantification of the PCR products with the dye SYBR Green I (Biogene) and the fluorescence of the dye-DNA complex detected by a fluorescence microplate reader (Molecular Devices Ltd.). As a comparison, the detection limit when we used p-nitrophenylphosphate colorimetric substrate (Sigma) was 10 Ϫ4 U of AP. These results demonstrate proof of principle of our novel approach and show that the indirect immuno-PCR methodology can be used to detect and quantify AP activity with very high sensitivity.
We also compared the detection limit of our approach with that of the highly sensitive AMPAK system (Dako Ltd.), an ultrasensitive amplification colorimetric system for AP that is comparable in its sensitivity to chemiluminescence, for the detection of AP and found that this indirect immuno-PCR is 100-fold more sensitive.
To calculate the reproducibility and precision of our assay, we used SYBR Green I to quantify the PCR products seen on our gels as described previously. Multiple assays were performed to detect 10 Ϫ6 U of free AP. The intraassay CV of the signal was 7.4% (n ϭ 8).
We then used the indirect immuno-PCR assay to analyze serial dilutions of commercial AP-antibody conjugates to confirm that the enzyme, in this configuration, was still able to use the 5Ј-phosphorylated dsDNA substrate. For this study, an anti-mouse IgG-AP conjugate (Sigma) and an anti-Chlamydia AP conjugate (DakoCytomation Ltd.) were used. Our results showed that the indirect immuno-PCR assay had a detection limit more than 100 000-fold lower than the standard colorimetric pNPP substrate and at least 1000 times lower than the AMPAK detection system with these conjugates (data not shown). This detection limit was comparable to that seen for free AP.
We also confirmed that the indirect immuno-PCR method functions well in a complete microplate ELISA procedure for Chlamydia (DakoCytomation Ltd.; data not shown), and optimization of this protocol is ongoing to measure sensitivity.
In summary, we have demonstrated proof of principle of our novel indirect immuno-PCR technique that links the presence of AP conjugate to PCR amplification. Because the technique works in a way completely different from that of traditional immuno-PCR, it offers an alternative approach and may circumvent some of the common problems associated with traditional immuno-PCR. Work is ongoing to fully exploit the potential of this new approach. One exciting development is the adaptation of the indirect immuno-PCR detection method to real-time amplification and detection PCR formats to replace the cumbersome gel electrophoresis procedure. This could allow the direct coupling of fully automated PCR instrumentation to existing immunoassay processing systems, thereby providing an opportunity to combine immunoassay and nucleic acid techniques in one instrument platform.
Long-lifetime fluorescent europium(III) chelate nanoparticles have been shown to be applicable as labels in various heterogeneous and homogeneous immunoassays. Assay performance can be improved when these intrinsically labeled nanoparticles are used in combination with time-resolved fluorescence detection. In several previous publications, we have shown the potential of nanoparticle labels in different assay applications. In heterogeneous assays, the dynamic range of assays at low concentrations can be extended (1) (2) (3) . Furthermore, the kinetic characteristics of assays can be improved by use of detection antibody-coated high-specific-activity nanoparticle labels instead of conventionally labeled detection antibodies (4 ) . In homogeneous assays, europium(III) nanoparticles have been shown to be efficient donors in fluorescence resonance energy transfer, enabling simple and rapid highthroughput screening (5 ) . Heterogeneous and homogeneous nanoparticle-label-based assays can be run with various sample matrixes, e.g., serum (3 ), heparin plasma (3 ), and mucus (S. Huopalahti, A. Valanne, T. Soukka, R. Vainionpää, T. Lö vgren, and H. Härmä, University of Turku, unpublished data).
In the present work we describe a kinetic, heterogeneous, one-step immunoassay application in which europium(III) nanoparticle labels are used in an all-in-one dry-reagent format (Aio!™) (6 ) to produce a simple, rapid, and sensitive sandwich-type assay for thyroidstimulating hormone (TSH). Conventionally, the Aio! technology is based on the europium(III) chelate label, but in the present work the chelate label was replaced by a nanoparticle label. TSH, a widely used thyroid disease marker and the most important single determinant of thyroid status (7 ), was selected as a model analyte because of the requirement for a low limit of quantification for thyroid diagnostics. Although thyroid diseases are not immediately life-threatening, TSH is a valuable analyte for a rapid testing. It is measured frequently; therefore, high cost-effectiveness can be achieved by enabling diagnosis during a patient's first visit to the doctor's office and by reducing the number of return visits.
The TSH sandwich assay was performed with anti-TSH monoclonal antibodies (Mabs) 5405 and 5409 (Medix Biochemica) for capture and detection, respectively; europium(III) nanoparticle labels (Seradyn Inc.; 107 nm in diameter); and Aio! dry reagent microtitration wells (Innotrac Diagnostics). The procedure for coating nanoparticles with the detection Mab is described in detail elsewhere (4 ). Biotinylation and immobilization of the capture Mab on the microtitration wells were performed as described previously (8 ) . Before label addition, the solid-phase Mab was insulated with 40 L of Aio! insulation layer solution (Innotrac Diagnostics) in an overnight incubation (35°C at 5% humidity). The nanoparticle labels were added to the wells in a 1-L volume (1.0 ϫ 10 8 nanoparticles/well), and the wells were dried under an air stream. The ready-to-use dry-reagent wells were stored in sealed aluminum bags at room temperature.
The kinetic one-step TSH assay was performed with the Aio! immunoassay system, in which 5 L of serum sample was applied in a 30-L assay volume into the dry-reagent wells and incubated for 10 min. The wells were then washed, and the long-lifetime fluorescence of particulate labels was detected to give a quantitative TSH result.
The design of the all-in-one, dry-reagent assay for TSH with use of the long-lifetime fluorescent nanoparticle label is shown in Fig. 1 . Because the kinetic assay was performed with an automated immunoassay system, assay times were relatively short (total assay time Ͻ15 min) with little hands-on time.
The detection limits (mean ϩ 2 SD of the zero calibrator) of the nanoparticle assays were 0.0012 mIU/L (7 fmol/L) and 0.02 mIU/L (111 fmol/L) when calibrators were diluted in assay buffer or serum-based matrix, respectively. The linear dynamic range of the assay was more than three orders of magnitude (Ͻ0.1 to 50 mIU/L). At the high end of the examined concentration range, we observed a deviation from linearity, but we detected no hook effect even at the highest concentration studied (100 mIU/L).
Within-and between-run imprecisions (CVs) were 4 -14% and 6 -17%, respectively. Recovery of 0, 0.5, 2.5, and 5 mIU/L TSH added to four serum samples was 90 -110%, except one value that differed by ϩ24%. Dilution of four samples with the zero calibrator in ratios of 1:2, 1:4, and 1:8 gave results within 10% of the expected values. For a method comparison of the nanoparticlelabel-based application (y) and AutoDelfia ® (x), an automated commercial assay (PerkinElmer Life and Analytical Sciences), the regression equation had a slope (SD) of 0.96 (0.021) and y-intercept (SD) of 0.12 (0.089) mIU/L. The mean values obtained with the nanoparticle and commercial assays were 2.82 and 2.83 mIU/L, respectively (S y͉x ϭ 0.49 mIU/L; R ϭ 0.988; n ϭ 54).
As can be seen from the difference plot in Fig. 1B , the mean percentage difference between the two methods was ϳ6%, and 48 of the 54 samples differed by Ͻ20%.
We have described a quantitative nanoparticle-labelbased one-step TSH immunoassay. The detection limits correspond to those for the fourth-and third-generation TSH assays. The large dynamic range well below and above the reference interval for TSH (ϳ0.5 to 5.0 mIU/L) (9, 10 ) allows detection of hypo-as well as hyperthyroidism. The sample and assay solution volumes are small, only 5 L and 25 L, respectively, and the required hands-on time is short. Furthermore, full automation of the assay is possible.
We conclude that the developed kinetic, all-in-one dry-reagent immunoassay using time-resolved fluoromeClinical Chemistry 50, No. 10, 2004 try has great potential as a rapid, cost-effective, and sensitive assay when antibody-coated, high-specific-activity europium(III) nanoparticles are used as labels. We believe that the analytical approach is applicable to various analytes and sample matrixes. Furthermore, this simple and rapid assay format could be beneficial, e.g., when time is critical concerning the life of a patient, such as for cardiac diagnostics. (1) (2) (3) (4) . At the base of the current Affymetrix process of synthesis of oligo-DNA probes is the use of nucleoside monomers protected with photo-removable groups (Fig. 1A) . Irradiation of the partially built oligomer with near-ultraviolet wavelengths (mainly 365 nm) deprotects the terminal hydroxyl group, and the use of appropriate masks allows for control of the sequence of the probe and the size of the features. The sensitivity of DNA to ultraviolet radiation limits the range of wavelengths usable for the photolitographic step to mainly the Hg atomic emission at 365 nm. Therefore, the choice of photo-removable hydroxyl protecting groups depends on the absorbance at this wavelength (4 ) .
Photo-Removable Protecting Groups for in
Our ongoing investigations concerning the fabrication of DNA microarrays have several goals, including increasing the rate and the efficiency of photo-deprotection. The rate of deprotection, or photospeed (PS), is a function of the molar absorptivity of the chromophore at the 
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Abstracts of Oak Ridge Posters wavelength of irradiation and the quantum yield of the desired photochemical product formation process. Increasing the molar absorptivity at 365 nm and the quantum efficiency of the process will generally lead to an increase in PS. In general, the rate and yield of photodeprotection can be controlled by tuning each of these variables.
Several coumarins and variants of nitro aromatic systems, such as nitrocoumarins, nitroanilines, and nitroindolines, were synthesized and studied for their photoreactivity (Table 1) . To screen this series of compounds, we synthesized the corresponding acetate derivatives and tested them in solution for their rate of photocleavage. The more interesting ones (e.g., those with a large PS or a large molar absorptivity) were synthesized as nucleoside-3Ј-phosphoramidites and tested for their rate of deprotection and the efficiency of DNA synthesis on a solid support.
For the solution photolysis study, we dissolved the acetate in methanol to reach an absorbance of ϳ0.1 at 365 nm. The solution was then irradiated with a 500 mW collimated mercury light source. The progress of the photocleavage was monitored by both ultraviolet absorbance and HPLC analysis. Half-lives (t 1/2 ) were calculated by linear regression analysis (4 ) of plots of ln(area of the species) vs time (t 1/2 ϭ 0.693/slope). PS was then calculated as the inverse of the half-life multiplied by the intensity of the light source expressed in Joules [PS ϭ 1/(t 1/2 ϫ intensity)]. A procedure for the measurement of the deprotection yield has been already described (4 ) .
Coumarins were chosen for their generally high molar absorptivity at the wavelength of irradiation. To take advantage of the fast and efficient photo-induced homolysis/heterolysis (5, 6 ) of benzylic ethers, we have functionalized several coumarins for this purpose. As anticipated, substitution on the aromatic ring with an electrondonating group (Et 2 N-or MeO-) enhanced the molar absorptivity at 365 nm as well as the rate of deprotection of the acetates. The deprotection/coupling efficiency for generation of T-oligomers using 5Ј-coumarin carbonylprotected dT-3Ј-phosphoramidites as monomers was Ͼ90%.
Encouraged by the results achieved with the coumarin series, we expanded the study to include another series of photogroups, nitrocoumarins. This series was chosen for their anticipated large molar absorptivities at 365 nm. Contrary to our expectations, however, nitro group substitution in either position 3 or 5 of the coumarin moiety decreased the molar absorptivity of the acetate derivatives up to 10-fold. This decrease was paralleled by a similar decrease in their rate of photocleavage. In line with these findings, during the photochemical study, we observed an absence of fluorescence for all of the nitro-substituted coumarin compounds. It is likely that substitution with a nitro group generates a low-lying excited triplet state that reduces the reactivity of these compounds.
Contrary to the series of compounds discussed above, the mechanism of photocleavage of substituted nitroanilines and indolines has been more extensively investigated (7) (8) (9) . The mechanistic pathway is dependent on the presence of water or other nucleophiles. Photo-induced generation of the excited triplet state triggers an intramolecular rearrangement and elimination of the acyl group (Fig. 1B) . We have studied a series of nitroaniline, nitroindoline, and nitroquinoline carbamates as possible 5Ј-OH photoprotecting groups.
In the case of the anilines, the molar absorptivity at 365 nm is dependent on the substitution on the aromatic ring. In fact, electron-donating groups increased the molar absorptivity and the PS. The deprotection/coupling efficiency, however, did not follow the same trend. The monosubstituted 4-methoxy analog had the best coupling efficiency (97%), followed by the unsubstituted aniline analog (93%) and finally the methylenedioxy analog, with a coupling efficiency of only 88%. Nitroindolines were faster than the anilines within the same pattern of substitution on the aromatic ring. Of this series the 4-methoxy analog was the fastest to react on irradiation (PS ϭ 5.0) and the one with the largest coupling efficiency (93%). Finally, in the case of the quinoline compound, the rate of photo-deprotection was 10-fold slower than that for the corresponding unsubstituted indoline. This result seems to be suggestive of a steric demand for the efficiency of the photocleavage. Unfortunately, the preparation of carbonate derivatives of nitroquinoline was complex, and we do not have data on the coupling efficiency.
In conclusion, several classes of compounds have been studied and shown to give fast and efficient photodeprotection of 5Ј-hydroxyl groups for in situ DNA microarray synthesis. These same compounds might find application in other areas of synthetic chemistry as well. By appropriate substitution it is possible to increase the molar absorptivity of the substrate and influence the rate of deprotection. The deprotection/coupling efficiency can also be altered, but the outcome is more difficult to predict. Our efforts in designing, synthesizing, and testing still more photogroups are ongoing. Ovarian cancer is the fifth leading cause of death from cancer in women and is the leading cause of gynecologic death in developed countries. Although the overall 5-year survival rate of patients with ovarian cancer is only 25%, the survival rate of patients diagnosed with early-stage ovarian cancer (I/IIa) approaches 90% (1 ). Therefore, a noninvasive diagnostic test that can detect early-stage ovarian cancer would be highly desirable, particularly if it could be coupled to a second, noninvasive diagnostic test such as transvaginal ultrasound. In a recently completed multiinstitutional protein expression profiling study encompassing 503 women from four institutions, we developed a three-marker panel that could distinguish women with early-stage ovarian cancer from healthy controls with higher diagnostic accuracy than could CA125 (area under the curve, 92% vs 77%) (2 ) . Purification and identification of the three markers revealed that they were a truncated form of transthyretin, full-length apolipoprotein A1, and an internal fragment of inter-␣-trypsin inhibitor heavy chain 4 (ITIH4).
Transthyretin is known to be cysteinylated and glutathionylated in addition to being truncated (3 ). ITIH4 is cleaved at multiple sites, generating numerous cleavage products (4 ) . Conventional immunoassays generally cannot simultaneously distinguish or quantify multiple posttranslationally modified forms of a protein or its isoforms.
Mass spectrometry (MS)-based assays have the advantage of being able to do so, but are often not considered to be quantitative. Because of the chromatographic nature of the ProteinChip ® array surface, surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-MS has the advantage of being quantitative (5 ) . When immunocapture is coupled with SELDI-TOF-MS, a single immunoassay can quantify multiple forms of an analyte. The immunocapture can be performed directly on the ProteinChip array surface (by use of a reactive surface array) or on beads coated with antibody. In the latter case, the bound material is eluted onto ProteinChip arrays.
Several antibodies to transthyretin and apolipoprotein A1 were evaluated for their performance in SELDI-TOF-MS-based ProteinChip assays. Selection criteria included dynamic range of linear response, specificity as determined by the number of peaks detected in SELDI-TOF-MS immunoassays, and antibody stability as assessed by the quantity of intact antibody present in SELDI-TOF-MS quality-control assays of the reagents. The two commercially available antibodies selected were rabbit anti-human transthyretin antibody (cat. no. A0002; Dako Cytomation Corporation) and mouse anti-apolipoprotein A1 antibody (cat. no. 178474; EMD Biosciences, Inc.). To generate antibodies to ITIH4, a peptide corresponding to the discovered biomarker for ovarian cancer derived from ITIH4 was chemically synthesized with addition of cysteine at the NH 2 terminus (SynPep, Dublin CA). The sequence is as follows: CMNFRPGVLSSRQL-GLPGPPDVPDHAAYHPF. The peptide was conjugated to keyhole limpet hemocyanin and injected into rabbits according to a 69-day standard protocol used by SynPep. Rabbit bleeds were collected, and ELISA tests to determine titers were performed by SynPep. Antibodies were purified by use of protein A and affinity chromatography.
For the immunoassays, we covalently linked the antibody to AminoLink ® Plus beads (Pierce Biotechnology). Beads were washed twice with 200 L of phosphatebuffered saline (PBS), pH 7.2, containing 1 mL/L Tween. Calibrants for transthyretin were purchased from Kamiya (K-assay Prealbumin Calibrator reagents) and were diluted 1:50 in the same buffer to a final volume of 100 L/assay well. For the ITIH4 assay, the antigen peptide stock described above was added to 100 mL/L normal human serum (cat. no. H-1388; Sigma) diluted in the same buffer to a final volume of 100 L/assay well. In a Sigma serum sample with no added antigen peptide, no endogenous peptide was detected. A serum titration curve was generated for the apolipoprotein A1 assay by use of pooled human serum (Intergen) diluted in the same buffer to a final volume of 100 L/assay well. The amount of apolipoprotein A1 in this particular lot of human serum was measured beforehand by ELISA in an independent laboratory and was reserved in aliquots solely for this purpose.
Reactions were performed in 96-well filter plates at room temperature for 2 h on a MicroMix shaker (DPC). At the end of the incubation, the beads were washed three times (3 The arrays were rinsed with water once for 1 min and then briefly allowed to air dry. For the transthyretin and apolipoprotein A1 assays, 1 L of 12.5 mg/L sinapinic acid (SPA) was added to each spot, dried, and then reapplied. For ITIH4, 1 L of 20% saturated ␣-cyano-4-hydroxy-cinnamic acid (CHCA) was added to each spot, dried, and then reapplied. For the external normalization purpose, 5 fmol of bovine insulin was mixed with CHCA and applied to each spot for the ITIH4 assay. SPA and CHCA were prepared in 500 mL/L acetonitrile-5 mL/L trifluoroacetic acid. Matrix was applied using the Biomek 2000 (Beckman).
The arrays were read in a PBSIIc ProteinChip reader, a time-lag focusing, linear, laser desorption/ionization time-of-flight mass spectrometer. All spectra were ac- 
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Abstracts of Oak Ridge Posters quired in the positive-ion mode. Time-lag focusing delay times were set at 400 ns for ITIH4, 900 ns for transthyretin, and 1200 ns for apolipoprotein A1. Ions were extracted by use of a 2.9-kV ion extraction pulse and were accelerated to final velocity by use of 20 kV of acceleration potential. The system used a pulsed nitrogen laser at repetition rates varying from 2 to 5 pulses/s. Typical laser fluence varied from 30 to 150 J/mm 2 . An automated analytical protocol was used to control the data acquisition process in most of the sample analysis. Each spectrum was the mean of at least 50 laser shots and was externally calibrated against a mixture of known peptides or proteins. Mass accuracy was ϳ0.05%.
An example of the SELDI-TOF-MS assay of the three markers is shown in Fig. 1 . The SELDI-TOF-MS transthyretin immunoassay, in contrast to the traditional nephelometric method, can simultaneously quantify and distinguish four forms of transthyretin: unmodified, cysteinylated, glutathionylated, and truncated. In our experience, cysteinylated transthyretin is the largest peak of these forms, and the truncated form is the smallest (Fig.  1A) . Although the SELDI-TOF-MS immunoassay for the ITIH4 peptide showed a single peak when performed on the peptide (Fig. 1B) , immunoassays performed on human serum revealed the antigenic peptide as well as a series of smaller peptides representing sequential Nterminal truncation. Although these truncations may arise in vivo or ex vivo, depending on the stability of the peptides, the addition of protease inhibitors had no effect on the intensity or pattern of fragmentation, suggesting that these truncations resulted from in vivo protease activity. Incubation for longer periods of time decreased the overall peak heights but did not alter the pattern of fragmentation. Incubation at room temperature gave slightly lower peak heights than incubation at 4°C, but like the length of incubation and addition of protease inhibitors, had no effect in overall pattern of fragmentation (data not shown). Results obtained with the apolipoprotein A1 assay are shown in Fig. 1C . The bottom graph shows the titration curve for apolipoprotein A1. The x axis shows the calculated amount of apolipoprotein A1 according to the ELISA data.
Data from a sample calibration curve for the ITIH4 assay are shown in Table 1 , along with the CV. The limit of detection (value with a signal-to-noise ratio of 5) was 0.037 mg/L. The range of linearity for the ITIH4 was almost two orders of magnitude. Within-run reproducibility was measured by assaying the pooled Intergen human serum five times on one plate; the mean (SD) concentration of the ITIH4 fragment (3273 Da) was 1.10 (0.2) mg/L (n ϭ 5; CV ϭ 14%). Between-run reproducibility was measured by assaying the pooled Intergen serum 10 times in separate assays; the mean concentration of the ITIH4 fragment (3273 Da) in the Intergen serum was 1.11 mg/L (n ϭ 16; CV ϭ 22%). Recovery experiments were done by measuring ITIH4 peptide added to PBS-Tween buffer as well in 100 mL/L Sigma human serum (which does not contain endogenous ITIH4 peptide). We calculated the amount of the peptide added to Sigma serum, based on the calibration curve generated with the PBS/Tween buffer, and compared this value with the predicted value. The mean recovery was 82% (range, 61-102%).
Several groups have used proteomics approaches to identify candidate biomarkers for ovarian cancer (6 -8 ) . Some approaches do not include purification and identification of candidate markers, choosing to rely purely on the pattern derived through multivariate statistics. In other cases, a candidate marker was identified and assayed by conventional techniques. However, SELDI-TOF-MS immunoassays can provide quantification of multiple analytes. Because these assays can simultaneously quantify posttranslationally modified forms of the target analyte, this approach may be preferred when quantification of these forms is required for diagnostic accuracy (9 -12 ) . These assays are currently being tested on a large series of serum samples from patients with ovarian cancer to determine which specific combination of posttranslationally modified forms of these proteins confers the highest diagnostic accuracy.
We thank an anonymous reviewer for many helpful suggestions. The completion of the Human Genome Project (1 ) is likely to accelerate the demand for nucleic acid diagnostics, one of the fastest growing segments of in vitro diagnostics. To meet this demand, fully automated, sensitive, and specific technologies for nucleic acid detection are needed.
Surface plasmon resonance fluorescence (SPRF) is an optical detection technology that offers kinetic analysis of biomolecular interactions in real time (2 ) . SPRF technology uses a sensor composed of a dielectric material coated with a thin layer of a noble metal. An evanescent field is generated at the metal-dielectric interface through interaction of p-polarized light with surface plasmons (oscillating electrons) under a resonance condition. The evanescent field excites a fluorophore localized near the metal surface, which in turn emits evanescent waves, generating surface plasmons at the fluorescence emission frequency. These propagating waves (plasmon-mediated emission) radiate through the metal film and dielectric material. This emission emerges as a cone of radiation in the dielectric material.
Application of SPRF for nucleic acid testing involves immobilization of synthetic oligonucleotide capture probes on the sensor surface (Fig. 1) . Biotin-tagged nucleic acid amplicons are hybridized to target-specific capture probes and detected with a streptavidin-fluorophore conjugate by monitoring of the plasmon-mediated emission over time. Because the evanescent field penetrates a short distance into the medium above the metal surface, the hybridized amplicons are selectively excited and detected. This feature of SPRF allows sensitive detection without a wash step to separate the free from the hybridized nucleic acids. The fluorescent emission is collected by a patented optical system, providing higher sensitivity than other similar techniques (2 ) . The rate of increase in fluorescence emission is reported as the SPRF signal in mV/min. The hybridization and fluorescence detection steps can be completed in less than 2 min, making this technology one of the most rapid nucleic acid detection methods available.
To evaluate the potential of SPRF for detecting nucleic acids, model systems using Chlamydia trachomatis, Neisseria gonorrhoeae, and coagulant factor V DNA sequences were developed. Thiol-modified oligonucleotide capture probes were synthesized on an Applied Biosystems EX-PEDITE TM Nucleic Acid Synthesis System and immobilized on the gold surface of SPRF sensors. Targets were purified from specimens by binding to silica in the presence of a chaotropic salt (3 ) The sensitivity of the SPRF technology for measuring nucleic acids was evaluated with plasmid DNA molecules. Various amounts (10 6 , 10, 5, 1, and 0 copies) of cloned C. trachomatis plasmid DNA were amplified and detected with C. trachomatis-specific capture probes. All reactions containing plasmid DNA produced strong positive SPRF signals, ranging from 800 mV/min for the amplified products of a single copy to 4520 mV/min when starting with 10 6 copies. In marked contrast, the sample lacking plasmid DNA produced no significantly measurable SPRF signal. These results show that SPRF is a very sensitive technology for nucleic acid detection when combined with DNA amplification. In fact, the combination can detect a single copy of the target sequence.
The specificity of the technology was evaluated by use of cloned DNA from C. trachomatis and N. gonorrhoeae. The products were generated by a duplex amplification reac- Thiolated oligonucleotide probes, immobilized on the gold surface of SPRF sensor, capture biotin-tagged nucleic acid amplicons. Binding of streptavidinfluorophore conjugate to hybridized amplicons localizes the fluorophore near the gold surface. Because of the short penetration depth of the evanescent field into the medium above the gold surface, the fluorophores bound to the hybridized amplicons are selectively excited. The excited fluorophores generate surface plasmons, which radiate into the substrate at defined angles. The plasmonmediated emission emerges from the substrate in the shape of a hollow cone.
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Abstracts of Oak Ridge Posters tion containing primers specific for each analyte and were detected with SPRF sensors individually coated with capture probes specific for either target. The assay for C. trachomatis was positive (SPRF signal ϭ 1870 mV/min) only when C. trachomatis plasmid was present. Background signal obtained by measurement of these amplicons on the N. gonorrhoeae-specific sensors was very low (30 mV/min) or negative. In addition, a positive signal (2520 mV/min) was obtained for N. gonorrhoeae only when the N. gonorrhoeae target was present. Again, background signal obtained with the C. trachomatis sensor was close to 0 (10 mV/min). When both plasmids were present in a mixed-target sample, positive SPRF signals were obtained with both the C. trachomatis (2100 mV/min) and N. gonorrhoeae (2260 mV/min) sensors. These results demonstrate that the SPRF system is very specific and can readily differentiate between the C. trachomatis and N. gonorrhoeae nucleic acid sequences.
The SPRF system was further evaluated for its ability to measure amplicons generated from target sequences in clinical specimens. Cervical swab and urine samples were obtained from SLR Research Laboratory. All had been certified as positive for either C. trachomatis or N. gonorrhoeae infection by SLR by use of a molecular diagnostic test (e.g., GenProbe PACE ® , Abbott LCx ® , or Roche Amplicor ® ). After isolation, the nucleic acid targets were amplified with the previously described duplex amplification reaction before SPRF detection. A total of 271 clinical specimens were evaluated, and the SPRF system produced complete agreement with the results reported by the vendor. These results suggest that the SPRF technology could be used for in vitro diagnostic applications.
The specificity of the system was further evaluated for its ability to detect nucleic acid sequences that differ only at a single nucleotide position, such as the factor V Leiden mutation. Genomic DNA was extracted from patient blood samples and used to generate both wild-type and mutant amplicons with a pair of primers common for both sequences. The amplicons were then measured with SPRF sensors individually coated with capture probes specific for either sequence. A total of 20 blood samples obtained from ARUP Laboratories were used for the evaluation. Genotypes of the samples were certified by ARUP or determined by direct nucleotide sequencing on an Applied Biosystems 373 XL DNA Sequencer.
Initially, three patient samples were tested, representing the wild-type, heterozygous, and Leiden homozygous genotypes, respectively. The results showed that the wildtype sample produced a much stronger SPRF signal with the wild-type sensor (2930 mV/min) than with the Leiden mutation sensor (180 mV/min). In contrast, the homozygous Leiden sample produced a much stronger signal with the Leiden mutation sensor (3420 mV/min) than with the wild-type sensor (80 mV/min), whereas the heterozygous sample produced SPRF signals that were approximately the same for both types of sensors (1480 mV/min for wild-type and 1020 mV/min for Leiden). Testing of the remaining samples confirmed the trend. The wild-type samples produced a signal with the wildtype sensor that was at least 8 times higher than the signal observed with the Leiden mutation sensor, whereas the homozygous Leiden samples produced a signal with the Leiden mutation sensor that was at least 16 times higher than the signal observed with the wild-type sensor. Again, the heterozygous samples produced approximately equal SPRF signals for both sensor types. Such results indicate that the SPRF technology is specific enough to readily distinguish between sequences that differ by only a single nucleotide and that the technology thus has potential for use in the detection of genetic diseases and single-nucleotide polymorphisms.
In summary, SPRF is suitable for rapid, sensitive, and specific detection of amplified nucleic acids. The system sensitivity was demonstrated by its ability to detect a single copy of plasmid DNA. The system specificity was demonstrated by its ability to differentiate between various infectious disease agents and to detect the single nucleotide mutation in the factor V Leiden sequence. The SPRF system does not require a wash step, and the assay can be completed in less than 2 min. This technology can easily be integrated into a fully automated nucleic acid testing system for high-throughput clinical screening. Double-stranded DNA probes consisting of a 5Ј-terminus-labeled fluorescent strand and a complementary strand labeled on the 3Ј terminus with a quencher have been exploited in homogeneous hybridization (2, 6, 7 ) . Fluorescence signal is generated when the fluorophore strand hybridizes with the target. When the quencher strand hybridizes with the fluorophore strand, the signal from the fluorophore is quenched. Morrison et al. (6 ) used probes consisting of strands of equal length and a competitive hybridization technology, whereas others have exploited probes consisting of strands with different lengths for detection of PCR products (2, 7 ) .
The use of stable and fluorescent lanthanide chelates has enabled the development of homogeneous assay technologies based on time resolution (8 ) . Time-resolved fluorescence-quenching assays (TR-FQAs), based on energy transfer from a lanthanide chelate to a nonfluorescent quencher, have been applied in various assays of hydrolyzing enzymes (9, 10 ) and are commercialized as TruPoint TM . The first homogeneous PCR assays with lanthanide-labeled probes used an environmentally sensitive terbium chelate, the fluorescence intensity of which changes on probe hybridization (3, 11 ) . Subsequently, the technology was further improved by use of additional quencher probes (12 ) . Recently, a combination of quenching and competitive hybridization has been applied for end-point detection of PCR products (13 ) .
The aim of the present study was to compare two homogeneous PCR assay approaches based on a duallabel TR-FQA: one in which the probes hybridize during PCR cycling (called TruPoint-PCR) and the other in which the probes hybridize with the single-stranded target produced by asymmetric PCR only after PCR cycling (called competitive TruPoint-PCR). Labeling of the oligonucleotides during solid-phase synthesis allowed simple and straightforward production of the probes. The performance of the assay was demonstrated with known genomic DNA samples, and its applicability was demonstrated in end-point and real-time monitoring of target amplification from as little as 1 ng of genomic DNA.
Previously genotyped (14 ) genomic DNA samples with wild-type, carrier, and mutant status for ⌬F508 of the cystic fibrosis transmembrane conductance regulator gene were used. The DNA was quantified by spectrophotometric analysis at 260 nm, and the samples were stored in aliquots at Ϫ20°C.
Oligonucleotides (Table 1) were synthesized by use of the Expedite Nucleic Acid Synthesis System (Perseptive Biosystems). To europium probes a ligand based on the 2,2Ј,2Љ,2ٞ-[(-2,2Ј:6Ј,2Љ-terpyridine-6,6Ј-diyl)bis(methylenenitrilo)]tetrakis(acetic acid) (15) (16) (17) (18) and to terbium probes a ligand based on the 2,2Ј,2Љ,2ٞ-{[6,6Ј-(pyrazole-1Љ,3Љ-diyl)bis(pyridine)-2,2Ј-diyl]bis-(methylenenitrilo)}tetrakis(acetic acid) (16, 19 ) was coupled to the 5Ј end during oligonucleotide synthesis. The ligands were from PerkinElmer Life and Analytical Sciences, Wallac. Treatment of the oligomer with lanthanide citrate converted the oligonucleotide conjugate to the corresponding lanthanide chelate (15 ) . A synthesis support was used to introduce a black hole quencher 1 (Biosearch Technologies) to the 3Ј end of the quencher oligonucleotide according to the manufacturer's instructions.
For TruPoint-PCR assay (Fig. 1A) , the detection probes (Table 1) were designed to hybridize with the specific target in temperatures above the primer annealing temperature in PCR. Thus, in PCR conditions, the detection probes can hybridize with the denatured, single-stranded target before the complementary strand is elongated from the primers, which resembles the TaqMan ® (Roche) assay. The quencher probe was designed to quench the signal of 
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Abstracts of Oak Ridge Posters the remaining europium-and terbium-labeled probes on hybridization at 30°C. For competitive TruPoint-PCR (Fig. 1B) , the probes were designed so that the detection-probe-target hybrids form only after PCR (at 40°C), after which the detectionprobe-quencher-probe hybrids form at room temperature. Thus, the probes do not hybridize during PCR cycling, and the difference in melting temperatures of the detection and quencher probes allows control of the competitive hybridization by temperature. In addition, asymmetric PCR was used to generate single-stranded PCR products.
TruPoint-PCR was performed in two replicates and in a total reaction volume of 50 L containing the detection and quencher probes, primers ( In TruPoint-PCR, thermal cycling (DNA Engine PTC-200; MJ Research) was carried out as follows: (a) for end-point PCR, 35 cycles of 95°C for 30 s, 56°C for 1 min, and 69°C for 1 min, followed by 30°C for 1 min, after which the fluorescence signals were measured through the caps at 30°C by a Victor 2 1420 Multilabel Counter (PerkinElmer Life and Analytical Sciences, Wallac); (b) for real-time PCR, 35 cycles of 95°C for 30 s, 56°C for 1 min, 69°C for 1 min, and 30°C for 10 s. Fluorescence measurement was performed at the end of the cycle as described above. Competitive TruPoint-PCR amplification differed from the TruPoint-PCR amplification with regard to probe and primer concentrations (Table 1) , PCR program, and measurement temperature. Cycling consisted of 35 cycles of 95°C for 30 s, 56°C for 1 min, and 69°C for 1 min, followed by 95°C for 8 min, 40°C for 20 min, and 22°C for 15 min. Europium and terbium signals were measured at room temperature.
The functionality of the probes was studied in hybridization using different concentrations of synthetic targets (Table 1) in PCR buffer lacking primers, deoxynucleotide triphosphates, and enzyme. Hybridization with TruPoint-PCR probes was performed at 69°C for 20 min and quenching at 30°C for 15 min. Hybridization with competitive TruPoint-PCR probes was performed at 40°C for 20 min and quenching at 22°C for 15 min. After quenching, the fluorescence was measured.
The functionality of the probes was demonstrated in hybridization. Black hole quencher 1 was found to be an optimal quencher of both europium and terbium fluorescence, with 99% quenching efficiency. For both assay approaches, the lowest detectable concentration of the synthetic target was 1 nmol/L (signal-to-noise ratio ϭ 2), and the assays were linear up to 30 nmol/L.
The performance of the TruPoint-PCR and competitive TruPoint-PCR assays was compared by amplifying different amounts of DNA samples with wild-type, carrier, and mutant status for ⌬F508. Fig. 1 , C and D, shows representative results obtained with the end-point competitive TruPoint-PCR assay. After a 35-cycle PCR, the two assay approaches gave equivalent results and a detectable signal (signal-to-noise ratio ϭ 2) with 1 ng of input DNA. Furthermore, DNA samples with wild-type, carrier, and mutant genotypes were correctly differentiated. The applicability of the TruPoint-PCR assay to real-time monitoring was also demonstrated. After 35 cycles, the real-time TruPoint-PCR assay gave detectable signal with 0.5-1 ng of input DNA (Fig. 1E and Fig. 1 in the Data Supplement that accompanies the online version of this abstract at http://www.clinchem.org/content/ vol50/issue10/).
In summary, the TruPoint-PCR and competitive TruPoint-PCR assays with dual-label TR-FQA allowed simultaneous detection of two alleles in one reaction, and the analysis of wild-type, carrier, and mutant DNA samples showed that the assays can specifically differentiate between these three genotypes. Although three to four probes are required for genotyping, the probes are relatively simple in design, including only one label moiety per probe. Furthermore, the lanthanide and quencher labels were directly coupled to the probes during solidphase synthesis, allowing simple production of highquality probes. Although direct comparison of TR-FQA PCR assays for different analytes is difficult, our results are comparable to those obtained by others. A TaqManlike TR-FQA PCR assay has been used previously to detect input of 33 cDNA molecules (signal-to-noise ratio ϭ 1.5) after 40 cycles of PCR (12 ) . In addition, a competitive TR-FQA PCR assay has been used to genotype 50 ng of input DNA (signal-to-noise ratios ranging from 1.5 to 3.8) in a 40-cycle PCR protocol (13 ) . We detected amplification product from at least 1 ng (equivalent to 330 target copies) of input DNA (signal-to-noise ratio ϭ 2) when we used 35 cycles of PCR, which is practical for genotyping if the starting material is limited or if samples from various resources are used.
In conclusion, the TR-FQA technology allows enhanced homogeneous detection of amplification products. The assays developed are suitable for simplified genotyping, requiring only preparation of the amplification reactions, thermal cycling, and fluorescence measurement. The endpoint measurement is the easiest way to record results, but the method also allows real-time monitoring. Furthermore, the closed-tube assay format eliminates contamination risk. The method is amenable to automation and suitable for the present instrumentation in many laboratories.
We thank Pirkko Grö nroos, Satu Kling, Kirsi Nenonen, and Kristiina Raunio for excellent technical assistance. Advances in instrument technology have led to extensive automation of the testing process. Use of information systems enables accurate and reliable tracking of laboratory test data and has facilitated the implementation of sophisticated informatics-based quality-control and quality-assurance programs. Application of quality-control systems using commercially available control samples has enabled the detection of analytical errors. In addition, use of laboratory data from patients has been helpful in detecting analytical errors as well as pre-and postanalytical errors. Examples of error detection schemes that rely on use of patient-derived data include checking of patient test results against predetermined limits or against previous values generated for the same patient (1, 2 ) . These detection schemes, referred to as limit checks and delta checks, respectively, are in common use. Other error detection schemes that have been devised include arithmetic checks and "interchecks" on analytes that are physiologically linked, such as the anion gap, and relationships between other analytes, such as albumin and globulin or aspartate and alanine aminotransferase (3 ). More recently, an automated expert system that can perform thousands of rule-based checks and hundreds of statistical checks of patient test results has been introduced (4 ) .
Clinical Evaluation of an Algorithm for Short Sample Detection on a Multi-analyte Panel Using a Point-of-
Among the potential errors that can occur during the analytical process is the addition of insufficient sample to the reaction mixture, either by itself or because of improper dilution of the sample with reagent diluent. This type of error may be caused by a variety of factors, including insufficient sample for analysis, insufficient reagent or sample diluent, obstruction of the sample probe by fibrin or other material, or increased viscosity of the sample. This type of error usually leads to abnormally low recovery of analytes and is often referred to as a "short sample". Many instruments use pressure transducers to verify system pressure and ensure sample integrity. However, systems that rely on pressure transducers for short sample detection do not measure the actual volume of fluid dispensed and are more likely to detect only catastrophic events in which the volume of delivered sample is significantly altered.
Errors attributable to short samples can also be identified by use of some of the previously mentioned datachecking algorithms. However, algorithms for this type of error detection usually require that the instrument performing the analysis be interfaced to a computer system capable of performing statistical analysis and accessing previous data that may not be available for all patients. To our knowledge, no algorithm that resides within the software of the analyzer itself has been specifically developed to analyze data resulting from "short" samples.
We developed an algorithm for the detection of short samples that resides completely within the instrument software on the Piccolo ® chemistry analyzer. This pointof-care analyzer can perform analyses on various test panels by use of self-contained, disposable reagent discs. After the introduction of 90 L of whole blood, serum, or plasma into the disc and insertion of the disc into the analyzer, the testing system performs all functions necessary for analysis. These functions include separating plasma from other cellular components (for whole blood samples), measuring the appropriate volume of plasma or serum and diluent needed for analysis, mixing of sample Clinical Chemistry 50, No. 10, 2004 and diluent, delivering the sample/diluent mixture to a reaction cuvette where all reagents are present in lyophilized form, and performing internal quality-control checks. The algorithm has been incorporated into the instrument software to identify short samples by use of reagent discs measuring analytes present in the Centers for Medicare and Medicaid Services (CMS) comprehensive metabolic panel (CMP), basic metabolic panel (BMP), and renal function panel (RFP) and, in addition, a specially designated MetLyte 8 panel; the latter is identical to the BMP except that creatine kinase is substituted in place of calcium.
A database of patient test results was obtained from a large population of hospital patients representing a wide variety of disease states. We analyzed the results of laboratory tests from more than 16 000 unique patient samples collected over a 60-day period. All samples were measured with an Olympus AU640 (Olympus America) and the manufacturer's reagents and procedures. The Olympus data were used to establish the frequency distribution of each analyte, from which we calculated the probability of obtaining a particular value. The probability of a short sample was determined by use of the best fit equation to the frequency distribution. The distribution is normalized to 100% for the mean expected value of the analyte. When the analyte value is greater than the mean value, there is no discrimination value for the probability of a short sample and the analyte value is assigned a probability of 1.0. The probability of a short sample for analyte values below the expected mean value is a function of the expected mean value and SD for the analyte. Analytes under stringent homeostatic control, such as electrolytes and other ions, provide greater discrimination for detection of short samples compared with other analytes, such as enzymes, that can show significant variability. Using the probability as determined by the distribution of analyte value, we defined a mathematical function describing the probability of a sample in a panel of results (e.g., BMP or CMP) having a particular set of results. The probability of a short sample was defined as:
where P ϭ probability; a, b, . . . x are analyte results; and n is the number of analytes measured in a reagent disc. After establishing the frequency distribution of analytes measured with the Olympus analyzer, we applied the mathematical function to a large number of samples from a diverse hospital population and determined the cumulative distribution of the probability of detecting short samples. The cumulative distribution of a particular test panel allows the selection of a particular probability to be used as the threshold value for identification of a possible short sample. The number of acceptable false-positive and false-negative test results can be selected based on the individual laboratories' acceptance of this type of error.
The mathematical model was tested with the ABAXIS Piccolo and MetLyte 8 reagent discs specifically manufactured to produce short sample situations in ϳ10% of reagent discs. This was accomplished by incorporating a defect within the sample transport siphon in the reagent disc. The plastic surface of the siphon was made more hydrophobic than normal, which led to fluidics errors. The analytes present in the MetLyte 8 included glucose, urea nitrogen, creatinine, sodium, potassium, chloride, total bicarbonate, and creatine kinase. We obtained heparinized whole blood and serum samples from 10 individuals. Each of the whole blood and serum samples was analyzed 10 times, and the short sample algorithm was applied to the data. The accuracy of the algorithm was assessed for each series of whole blood or serum replicates by comparing the expected serum or whole blood values (mean Ϯ 2.0 SD) with the algorithm.
Of a possible 200 sample runs with MetLyte 8 reagent discs, 2 runs were aborted by the Piccolo instrument because of failure of the internal quality-control checks of the reagent disc during sample analysis. Using the mean Ϯ 2.0 SD as the acceptable target range for replicate results, we identified 24 sample runs that were considered to be short samples. The incidence of short samples, 12.1%, was close to the anticipated incidence of 10%. At a probability threshold of 0.50, the algorithm correctly identified 19 short samples. There were five samples with up to four analytes below the expected measured values that were not identified as short samples by the algorithm. Finally, one sample was incorrectly classified as being a short sample. Thus, when we used an algorithm threshold of 0.50, the sensitivity, specificity, and positive and negative predictive values of the algorithm were 0.79, 0.99, 0.95, and 0.98, respectively. Decreasing the probability threshold of the algorithm to 0.45 would have led to the correct identification of 21 of 24 short samples; however, 1 additional sample would have been incorrectly classified as being a short sample. The sensitivity, specificity, and positive and negative predictive values obtained with the algorithm at a threshold of 0.45 were 0.88, 0.99, 0.91, and 0.99, respectively.
As expected, analytes with narrow probability distribution ranges were more useful in the prediction of short samples. The inclusion of enzymes present in the various CMS panels that we evaluated was found not to be useful for detection of short samples because of the magnitude of increase that might be observed in some patients.
We also tested the algorithm by serially diluting samples. This procedure allowed us to evaluate the sensitivity of the algorithm for the identification of short samples. Using this technique, we found that samples short by as little of 5% of their required volume for analysis could be detected by the algorithm. However, the sensitivity for detection of short samples is dependent on several factors, including the combination of analytes in the test panel and the analyte concentrations used in the calculations.
In summary, we developed an algorithm to detect short samples by evaluating results from numerous patient samples and determining the population distributions for these analytes. The algorithm makes use of the probability distributions for most of the analytes present in the panel. Analytes, such as enzymes, that may show extreme vari-
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Abstracts of Oak Ridge Posters ability are not useful in the algorithm. The greatest challenge for developing such an algorithm is to adjust the cutoff threshold that permits detection of true short samples and can differentiate these from patient samples for which the results are correct. One drawback of our model is that the initial probability distribution was based on results obtained with the Olympus analyzer for a hospital population. However, correlation studies performed between the Olympus and Piccolo analyzer enabled us to account for any differences in analyte recovery between instruments. In addition, although the algorithm was developed and tested with samples from hospital patients, the algorithm should perform equally well in the outpatient setting, where the incidence of abnormal results is less than that seen in hospital patients. Further development and refinement of the algorithm, especially in abnormal populations such as oncology and dialysis patients, is being conducted. Although the algorithm was developed for use with the ABAXIS Piccolo, the algorithm is applicable to any instrument that performs analysis of test panels. Staphylococcus aureus (SA) is one of the most important human pathogens, causing both nosocomial and community-acquired infections (1, 2 ) . The occurrence of methicillin-resistant SA (MRSA) has increased steadily worldwide and now accounts for a substantial portion of all staphylococcal infections in US hospitals (3 ) . To develop preventive measures, a rapid screening method, along with accurate and timely identification of MRSA, is essential. The existing techniques for doing so are either time-intensive (culturing of bacteria on selective media), relatively insensitive (use of latex agglutination), or expensive and easily susceptible to operator error (such as PCR).
Sensitive Assay for Identification of Methicillin-Resis
We describe a method designed for clinical laboratories using oligonucleotides conjugated to gold nanoparticles. We avoid radioactivity, fluorescence, or target amplification (such as PCR), and use a simple and rapid hybridization-based approach in a microarray format, with ClearRead TM technology to detect specific genomic sequences (4 ).
The ClearRead procedure involves a two-step process: the first involves the hybridization of target to oligonucleotides conjugated to gold nanoparticles as well as oligonucleotides attached to a solid matrix; the second step involves the catalytic deposition of silver on the gold nanoparticle, providing a sixfold amplification of signal (Fig. 1A) (4, 5 ) . The differentiation at isothermal hybridization temperatures is a result of the sharp melting transitions characteristic of nanoparticle probes (5 ). Previous methods based on this property (6, 7 ) have required the use of PCR and have not directly assayed for genomic DNA. Our assay, on the other hand, requires minimal amounts of genomic DNA (ϳ500 ng, or ϳ10 8 DNA molecules) and has been used to reliably identify MRSA from liquid cultures, based on the detection of the mecA and tuf genes. Resistance to methicillin is mediated by the presence of penicillin-binding protein 2a, encoded by the mecA gene (8, 9 ) . We are also able to identify polymorphisms in the tuf gene (10 ) that are characteristic for SA.
We applied our technology to screen a staphylococcal clinical panel, after growth in liquid medium, and found excellent correlation with culture results as well as standard coagulase tests (100% correlation). Our assay typically uses a hybridization of 30 min, and our proprietary detector, the Verigene ID TM (Nanosphere, Inc.). The Verigene ID takes advantage of the strong light-scattering properties of the silver-enhanced gold nanoparticles (11 ), thereby eliminating the need for the high-powered lasers and photomultiplier tubes typically used in instrumentation for the detection of fluorescent signals against a glass surface. Light-emitting diodes in combination with a complementary metal oxide semiconductor sensor are used for detection. The technology uses the slide itself as a waveguide, which allows the particle labels to scatter the evanescent field, giving even distribution of excitation light across the entire surface of the glass slide. This illumination methodology for the detection of hybridization events was first described by Stimpson et al. (12 ) as a means of performing single-nucleotide polymorphism analysis through measurement of the real-time melting behavior of DNA from a surface. Instead of using white light, the Verigene ID has been optimized to collect specific wavelengths to suppress background contributions. The imaging system allows sensitive detection of the proprietary Nanosphere gold labels. We also performed studies demonstrating the ability of the system to differentiate MRSA samples with as little as 5 min of hybridization time.
Oligonucleotide synthesis was performed with phosphoramidite chemistry on an Applied Biosystems ExpeClinical Chemistry 50, No. 10, 2004 dite 8909 DNA synthesizer. Modified oligonucleotides were prepared and loaded on the 13-nm diameter gold nanoparticles as described previously (13, 14 ) and were then designated as "probes". Oligonucleotides that were attached to the microarray surface were designated as "captures". Each microarray slide contained 10 test wells, such that 10 different samples could be tested per slide. Each test well had three test spots for mecA, three test spots for tuf, and nine negative-control spots. The hybridization cassette had 10 individual, spatially separated hybridization wells. An image of this hybridization cassette can be seen at www.nanosphere-inc.com. The specific oligonucleotide sequences used were 5Ј-TTCCA-GATTACAACTTCACCA-3Ј (mecA capture) (4 ), 5Ј-GCACTTGTAAGCACACCTTCAT-3Ј (mecA probe), 5Ј-CCATTCTTCTCAAACTATCGT-3Ј (tuf capture), 5Ј-TTCTATTTCCGTACTACTGACGTAACT-3Ј (tuf probe), and 5Ј-ATCGACTCCCGCAGACACCTTCTC-3Ј (negative-control capture). The negative-control sequence was derived from the human mutant methylene tetrahydrofolate reductase gene (15 ) after BLAST searches to ensure lack of cross-hybridization.
Arrays were printed on either NoAb (NoAb Biodiscoveries) or CodeLink (Amersham Biosciences) modified microscope slides by use of a Genomic Solutions Prosys Gantry (Genomic Solutions) with either SynQuad noncontact dispensing nozzles or Stealth SMP3 (Telechem International) split pins. Each spot on each array ranged from 200 to 400 m in diameter after printing. Regardless of slide type or dispensing method, amine-modified oligonucleotides were suspended in 150 mmol/L sodium phosphate, pH 8.5, at ϳ100 mol/L. Slides were arrayed at low humidity (relative humidity Ͻ30%) and subsequently rehydrated in a humidity chamber (relative humidity Ͼ70%) for ϳ18 h. Slides were then dried, washed to remove excess oligonucleotides, and stored in a cabinet desiccator (relative humidity Ͻ20%) until use.
We received 48 Staphylococcus isolates as swabs from a local hospital microbiology laboratory, where they had been identified as 29 coagulase-negative Staphylococcus (CoNS) and 19 S. aureus. They were inoculated into tryptic soy broth (TSB) and grown overnight at 37°C. A loopful from the overnight culture was grown for 24 h at 37°C on tryptic soy agar containing 50 mL/L sheep blood and on mannitol salt agar containing 6 mg/L oxacillin. Colony morphologies and hemolytic patterns were recorded for each sample. Eight samples showed colonies with mixed hemolytic patterns. Twelve samples (2 typed as CoNS and 10 typed as S. aureus) showed strong growth on oxacillincontaining agar. For those 12 samples, a loopful of cells representing multiple colonies was picked from the MSAoxacillin plate, grown overnight in TSB at 37°C, and frozen with glycerol at Ϫ80°C. The remaining samples were picked from blood agar plates and grown and frozen similarly. These frozen cultures were used to inoculate TSB for growth of cells for DNA isolation and growth on blood agar for use in phenotyping. Confirmatory testing was conducted with the OXOID Staphytect Plus Kit (A), genomic DNA is hybridized to oligonucleotides conjugated to 13-nm gold nanoparticles as well as to oligonucleotides attached to a solid matrix in a microarray format. The resulting signal is amplified and visualized by the catalytic deposition of silver on the hybridized gold nanoparticle and read by the Verigene ID detector.(B), 500 ng of purified genomic DNA from MRSA, MSSA, or MSSE was hybridized for 5, 15, or 25 min at 40°C, using a multiplex mixture of mecA and tuf nanoparticle probes. Each sample was separately hybridized on four different microarrays, and each microarray had six specific captures for the tuf gene. Data for every slide are shown; each data point shown is the median spot intensity of six specific spots (bars, SD). As before, a threshold was generated using the mean intensity values ϩ 3 SD of nine negative-control spots per well. Hyb. Time, hybridization time.
(Oxoid), using conditions recommended by the manufacturer, or by growth in TSB containing various concentrations of oxacillin (0, 0.25, 0.5, 2.0, and 4.0 mg/L) for 21 of the samples. Cells grown in TSB were lysed with achromopeptidase, and DNA was isolated by use of the QIAGEN Genomic DNA 20/G protocol. DNA samples were blinded and screened by our ClearRead technology in a microarray format. We hybridized 500 ng of purified genomic DNA from each sample for 30 min in a buffer containing 200 mL/L formamide, 5ϫ standard saline citrate, 0.5 mL/L Tween 20, and a multiplex mixture of mecA and tuf nanoparticle probes (at 100 and 250 pmol/L, respectively), at 40°C (n ϭ 36 for each sample) in a final volume of 50 L. Slides were washed in 0.5 mol/L NaNO 3 , and signal was developed for 3 min at room temperature by use of our proprietary silver development solution [prepared at Nanosphere, Inc, but similar in composition to an equimolar solution of reagents from Sigma (cat. nos. S5020 and S5145)]. Slides were scanned and imaged with the Verigene reader, with an exposure time of 199.8 ms, and data were analyzed by use of JMP software. Intensity values for every test spot were collected. Each sample was hybridized on 12 separate microarray slides, 1 test well per slide, to make a total of 36 separate data points for each sample (12 microarray slides ϫ 3 spots per slide).
A threshold was generated using the mean intensity values ϩ 3 SD of the nine negative-control spots per well. A positive response was defined as an intensity value above the threshold for that sample well.
The success rate was 100% compared with the results obtained from bacterial culturing in the presence of oxacillin as well as from coagulase testing; all MRSA, methicillin-sensitive SA (MSSA), and MR/MS non-SA (MRCoNS and MSCoNS) were correctly identified (8 of 8, 9 of 9 and 29 of 29 samples, respectively).
Purified genomic DNA, extracted from culture, from MRSA, MSSA or from methicillin-sensitive S. epidermidis (MSSE) were screened as described previously. Briefly, 500 ng of purified genomic DNA was hybridized for 5, 15, or 25 min in a multiplex mixture of mecA and tuf nanoparticle probes at 40°C. Slides were washed, signal was developed, spots were scanned and imaged, and data were analyzed as described above. Each sample was separately hybridized on four different microarrays, and each microarray had six specific captures for the tuf gene, making a total of 24 individual data points per target per condition (4 slides ϫ 6 specific captures; n ϭ 24 each). As before, a threshold was generated by use of the mean intensity values ϩ 3 SD of nine negative-control spots per well. A sample was designated as positive if the specific intensity values were above the threshold value for each individual well.
The results of this experiment are shown in Fig. 1B for the tuf gene. After 5 minutes of hybridization at 40°C, MRSA and MSSA were clearly differentiated from MSSE with use of 500 ng of genomic DNA (equivalent to ϳ10 8 molecules of DNA; also the approximate number of bacteria present in a single bacterial colony), a mock hybridization conducted with target replaced by water (designated as no-target), and the Verigene ID. These values are comparable with those reported previously by Jenison et al. (16 ) , although they used a much longer hybridization time (2 h) for detection of an equivalent copy number of mecA molecules from genomic DNA. We also have preliminary evidence (data not shown) that hybridization can be completed in ϳ1 min, depending on the amount of genomic DNA target used. We attribute the difference in hybridization rates to the increased sensitivity provided by direct detection of gold nanoparticle probes (4 ), because Jenison et al. (16 ) indirectly detected their biotin-labeled detector probes by use of a sandwich anti-biotin-horseradish peroxidase system, as well as the fact that we use a three-dimensional slide substrate (17 ) .
In conclusion, we have demonstrated technology that uses genomic DNA, eliminates the need for generating PCR target, is specific, does not require fluorescent labels, and uses a low-cost detector. Our use of gold-nanoparticle probes makes the assay ultrasensitive (that uses the equivalent of DNA from a single isolated colony), and slides can be archived after processing because the goldderived signal is not susceptible to photobleaching, in sharp contrast to fluorescence-based technologies.
Although we report reliable detection and differentiation of MRSA with use of 500 ng of genomic DNA, the sensitivity of our assay is considerably greater, extending at least out another two orders of magnitude, to at least 2.5 ng (ϳ5 ϫ 10 5 molecules) of unamplified bacterial genomic DNA with no loss of specificity and without any alterations in buffer composition or assay conditions (our unpublished data). These results compare very favorably with other studies (3, 4, 18 ) , in spite of the fact that we use complex genomic DNA in our assays. In developing a biologically relevant assay for detection and differentiation of MRSA, we have not been attempting to push the bounds of sensitivity. The combination of reliable specificity, high sensitivity, and low cost make this technology a viable option for widespread clinical use.
We thank Sung Jon Lee for help with bacterial culturing and DNA extraction and Hao An for assistance in sequence design. We acknowledge the intellectual contributions of James Storhoff and Susan Hagenow. We also acknowledge the manufacturing and engineering groups at Nanosphere, Inc., for technical support. Automated clinical chemistry analyzers were first introduced as single-and multichannel continuous flow analyzers in the 1960s (1, 2 ) . Ongoing evolution of analyzers has been driven by two factors: (a) increased demand by clinicians for rapid turnaround times (TATs); and (b) a need to decrease the cost of producing laboratory results and to consolidate laboratory testing into fewer workstations. The diagnostic industry has responded to this need by developing analyzers that have high throughput and expanded test menus, and perform both clinical chemistry assays and immunoassays on a single platform. As a result of these technical innovations, analyzer throughput and assay TAT are now dependent on such factors as (a) tests ordered on samples, (b) the number of samples loaded on a analyzer, and (c) the STAT-vs-routine ratio. Selection of the most appropriate analyzer to meet laboratory TAT consistently is no longer a trivial exercise of dividing the total number of daily tests by an analyzer's hourly throughput to determine whether it will meet laboratory needs. The goals of this study were to determine the feasibility of using MedModel 2001 (Promodel Corporation) software to develop a simulation model of the ci8200 integrated chemistry and immunoassay analyzer manufactured by Abbott Diagnostics, to estimate the percentage error in the model's predictions of test TAT, and finally, to use the validated model to evaluate the impact of increased routine test volumes on the TAT of STAT samples.
Use of Computer Simulation to
A simulation model of a clinical analyzer uses computer software specifically designed to imitate and capture an analyzer's dynamic behavior to study its performance under different conditions. Researchers in Europe and the United States have used computer simulations to study various aspects of clinical laboratory operation, including staff assignments, evaluating the queue length, and priority handling and processing TAT for different sample types (3) (4) (5) (6) (7) (8) (9) . However, there are no published reports using computer simulation specifically to predict the minimum, maximum, and mean TATs and the test throughput of an analyzer. There are two basic types of simulation techniques: discrete event and continuous simulation. Discrete events are instantaneous actions occurring at unique points in time. Examples of discrete events include a sample arriving in the laboratory and being loaded in an analyzer rack, and the analyzer rack being loaded in an instrument. These events cause a change in system states. In this model the computer maintains a timing device (simulation clock) that advances with each event that takes place at a fixed time point. If an event represents the initiation of an activity that will conclude in the future, the simulation will add the completion time to a list of future events and advance the clock when the next event is due. Discrete event simulation uses statistical methods for generating random behavior and estimating model performance. Continuous simulation models represent actions uninterrupted over time (e.g., models simulating biochemical reactions, temperature logs, and the flow of water in rivers).
The Medmodel 2001 (Promodel Corporation) software is discrete event simulator software. Using this software, we simulated the processes that occur on the ci8200 chemistry and immunoassay analyzer (see the flow diagram in Fig. 1) . Briefly, samples are programmed to arrive at a certain sample arrival cycle. Using defined attributes, laboratory personnel identify arriving samples and randomly assign them one or more tests. The samples are 1952 Abstracts of Oak Ridge Posters then loaded on the rack, with the maximum number being determined by the holding capacity of the rack. In a typical laboratory, technologists try to optimize sample loading by waiting until the rack is completely filled or by waiting for a specified time after the arrival of the first sample. This condition is simulated by use of the code within MedModel software "LOAD 5 IN N(15,2) seconds". This means that the technologist will load 5 samples, if available, or will wait for a time period that is randomly selected between 13 and 17 s to load the rack on the analyzer. The rack with the sample is then moved to the pipetting stations. The ci8200 is a lock-step analyzer, and the time duration or sample cycle time for an individual lock step determines the theoretical throughput of the analyzer. The lock-step duration for chemistry assays and immunoassays are 4.5 and 18 s, respectively. Thus, based on the test attributes assigned to a sample, the pipettor is used for 18 s with each immunoassay test and 4.5 s with individual chemistries. The only exception is when sodium, potassium, and chloride are ordered on a sample. In this case, the pipettor is used for 4.5 s for all three tests. After the sample cycle time has elapsed, the model creates an aliquot, which is routed to an available cuvette on the appropriate chemistry or immunoassay module. Using the "create" function, we were able to attach the attributes of the mother sample to each daughter aliquot. Once all samples in a rack are pipetted, the rack is routed to its original position on a retest sample handler (RSH). When the aliquot arrives at a processor, it decreases the capacity of the processor by 1 and waits 9.72 or 29.4 min for chemistry and immunoassay tests, respectively. For electrolytes (Na ϩ , K ϩ , Cl Ϫ ) and STAT immunoassays, the test times are 3 and 14.7 min, respectively. Once all aliquots for a sample have waited for the assigned time, they exit from the model, triggering a global variable to change states from 1 to 0 or vice versa. This change tells the software that all tests have been completed on a sample, triggering the log file to capture the TAT for the exiting sample.
Validation of the ci8200 model was done by running 200 routine and 20 STAT samples on 3 separate days. The test distributions for routine samples were 55% chemistry, 23% chemistry and immunoassay, and 22% immunoassays. For STAT samples, the distributions were 40%, 30%, and 30%, respectively. The following four routine and STAT sample scenarios were run each day: 200 routine; 200 routine with 10% repeats; 200 routine and 20 STAT; and 200 routine, 20 STAT, with 10% repeats. The numbers of tests run on the ci8200 for each scenario ranged from 1281 to 1434 for chemistries and 129 to 147 for immunoassays. The tests ordered on STAT samples were Chem 7 ϩ ␤-human chorionic gonadotropin (␤-hCG; 20%); Chem 7 (30%); Chem 7 ϩ troponin I ϩ creatine kinase-MB (CK-MB; 35%); and ␤-hCG (15%). The tests ordered on routine samples were ␤-hCG (4.5%); ␤-hCG ϩ Chem 7 (3.5%); troponin I ϩ CK-MB (4%); Chem 10 (6%); health panel-20 Chemistry test panel (1.5%); Chem 4 (1%); Chem 6 (7%); Chem 7 (12%); Chem 7 ϩ troponin I ϩ CK-MB The validated model was then used to study the impact of increasing routine test volumes on TATs of STAT samples. Using the arrival pattern of stat and routine samples at our institution, we tested the effect of increased routine test volume on TAT of STAT samples. This was done by simulating the following scenarios: 1000 routine and 320 STAT samples; 1200 routine and 320 STAT samples; 1400 routine and 320 STAT samples; 1600 routine and STAT samples; 1800 routines and STAT samples; 2000 routine and STAT samples; 2200 routine and STAT samples; and 2400 routine and 320 STAT samples. The tests ordered on these samples were same as those used in the validation study.
The experimental and simulated TAT and throughput results are compared in Table 1 . The simulated throughput was slightly less (Ϫ3.25% to Ϫ5.23%) than the actual (experimental) throughput. These differences, however, were not statistically significant (P ϭ 0.15). A unique feature of the ci8200 chemistry and immunoassay integrated analyzer is the RSH sample handler. Whenever a STAT sample is loaded on the analyzer, the RSH "pick and place" arm picks up the sample and immediately presents it to the pipetting station. If a routine sample is already present at the station, it is preempted, thereby allowing rapid sampling of STAT samples. This could cause an increase in the routine sample TAT while maintaining a constant STAT sample TAT. As seen in Table 1 , this is indeed the case. The simulated mean TAT for routine samples increased by 98 min for chemistry and immunoassay tests when the sample load arriving over a 24-h period increased from 1000 to 2400 tubes. For STAT samples, however, the mean TAT was relatively unchanged, ranging from 12.22 to 12.52 min and from 20.06 to 20.49 min for chemistry and immunoassay tests, respectively.
In conclusion we found computer simulation to be a powerful tool to evaluate test throughput and TAT of a clinical analyzer. Developing a simulation models takes 3-4 weeks, and the information needed to develop a model for a clinical analyzer is usually available in the public domain or directly from representatives of various diagnostic companies. MedModel 2001 is robust software and allows a user to simulate all important functionalities of an analyzer. Although these models do not give an exact simulation of an analyzer, prediction of analyzer throughput and TAT with less than 5-10% error from actual analyzer results is possible. Numerous diagnostic companies have developed or are developing simulation models of this type to help the laboratory make an informed decision. However, before accepting the results of a simulation, laboratorians should (a) visually compare the actual sample-processing logic of the analyzer with the simulated analyzer by reducing the speed of the simulation, (b) compare the simulated TAT with actual instrument TAT to ensure that the two agree with less than 5-10% error, and (c) estimate the error in the simulated throughput vs the real throughput. We believe that in this era of "getting it right the first time", simulation studies of this nature are of the utmost importance to ensure that the chosen analyzer will meet the desired TAT with the laboratory's specific test ordering and sample arrival pattern. two general microarray-based methods for genotyping. One approach involves arraying thousands of short oligonucleotides on glass slides for detection of many singlenucleotide polymorphism (SNP) loci in target DNA (1 ). This method is particularly well suited for genotyping thousands of markers in a limited number of individuals (2) (3) (4) (5) (6) . The other approach involves arraying amplified PCR products on glass slides to detect a few SNPs in a large number of samples. Recently, Flavell et al. (7 ) developed a tagged microarray marker approach for scoring thousands of samples for a codominant molecular marker. Biotin-terminated allele-specific PCR products are spotted unpurified on streptavidin-coated glass slides and visualized by hybridization of fluorescent detector oligonucleotides to tags attached to the allele-specific PCR primers. The tagged microarray marker approach is an efficient method for genotyping thousands of samples on a glass slide. However, reliable allele-specific PCR conditions are needed. Moreover, the expensive streptavidincoated glass slides can be stored for only 3 days in phosphate-buffered saline.
For many applications in the field of biological research, PCR products are the more convenient probe molecules (8 ) . We have developed a microarray-based method, based on dual-color fluorescence hybridization, for genotyping of SNPs in thousands of individuals (9 ) . The experiment successfully demonstrated that PCR products subjected to dual-color hybridization on a microarray could used to analyze molecular markers. However, two fluorescently labeled detector probes are required for each SNP, and the cost is high when many different SNPs need to be analyzed.
In this report, we describe a high-throughput method for genotyping of any SNP from hundreds of individuals by use of two pairs of secondary labeled universal oligonucleotides (detectors).
Peripheral blood was obtained from 196 patients suffering from different types of hematologic malignancies. All were diagnosed cases referred from ZhongDa Hospital and The First Affiliated Hospital of Nanjing Medical University (Nanjing, China). Genomic DNA was isolated by standard methods using proteinase K digestion and phenol-chloroform extraction. The genotype of the human mismatch repair gene hMLH1 at the G93A locus was amplified by PCR with 0.4 mol/L each of the forward (5Ј-AGTAGCCGCTTCAGGGA-3Ј) and reverse (5Ј-AG-GACGGTGCGGTGAGAGTG-3Ј) primers, as described previously (10 ) . The profile consisted of an initial melting step of 4 min at 94°C, followed by 35 cycles of 1 min at 94°C, 1 min at 55°C, and 2 min at 72°C; with a final elongation step of 7 min at 94°C. PCR mixtures contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.0 mM MgCl 2 , 200 M each of the deoxynucleotide triphosphates, and 1.25 U of Taq DNA polymerase (TaKaRa) in 50 L. PCR was preformed in a PTC-225 thermocycler (MJ Research).
PCR products were purified by use of a QIAquick column (Qiagen). The eluted PCR products were dried under reduced pressure and resuspended in 3ϫ standard saline citrate (SSC). Each sample was then diluted with 3ϫ SSC supplemented with 1.5 mol/L betaine to a final concentration of 200 g/L and transferred to new 384-well plates for arraying. After printing, the microarrays were dehydrated for 30 s in a humid chamber and then snap-dried for 2 s on a hot plate (100°C). The DNA was then cross-linked to the surface by subjecting the slides to 60 mJ of energy (Stratagene Stratalinker) and baking them for 2 h at 80°C. The rest of the poly-l-lysine surface was blocked by incubation for 15 min in a solution consisting of 1-methyl-2-pyrrolidinone (Aldrich) and 1 mol/L boric acid (pH 8.0). Directly after the blocking reaction, the bound DNA was denatured by incubation for 2 min in distilled water at 95°C. The slides were then transferred to a bath containing 950 mL/L ethanol at room temperature, rinsed, and then spun dry in a clinical centrifuge. Slides were stored in a closed box at room temperature until used.
The sequences for the probes and fluorescent detectors (Shenyou Inc.) used for genotyping the hMLH1 G93A polymorphism are shown in Table 1 . Probes 93G and 93A were mixed in equimolar amounts and suspended in unihybridization solution (3:1 dilution by volume; Telechem). Hybridization was conducted in a moist hybridization chamber under a cover slip at 37°C for 4 h. After hybridization, the slides were rinsed and then washed successively at room temperature with 2ϫ SSC containing 1 g/L sodium dodecyl sulfate, 0.1ϫ SSC containing 1 g/L sodium dodecyl sulfate, and deionized water (5 min for each wash), and dried by centrifugation at 38g for 5 min. Detectors A-B, AЈ-BЈ, C-D, and CЈ-DЈ Table 1 . Oligonucleotide sequences used in this study. 
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In principle, probe hybridization should produce different spot colors depending on the SNP genotype, as shown in Fig. 1A . The homozygous wild type yielded strongly fluorescent Cy3 spots (green fluorescence). A strongly fluorescent Cy5 spot (red fluorescence) was produced by the homozygous mutant. The heterozygote yielded both Cy3 and Cy5 spots; because of overlapping, the fluorescence was strongly "yellow".
The results obtained for 196 genomic DNA samples from patients with hematologic malignancies analyzed for the G93A locus are shown in Fig. 1B . The complete array was spotted in quadruplicate, and the fluorescence pattern was highly reproducible between replicates (Fig.  1B) . Spot homogeneity was dependent on the variation in the DNA concentration across a spot. Supplementing SSC with 1.5 mol/L betaine yielded much more homogeneous spots (11 ) .
The fluorescence signals from seven representative samples were quantified (Fig. 1C) . Homozygous samples had a fluorescence ratio of ϳ10 (stronger:weaker signal), whereas heterozygous samples had ratios near 1.0. The microarray results were additionally validated by sequencing (data not shown).
The method described here requires only simple PCR and scoring. The set-up involves simple PCR and scoring by microarray scanning, which has been well developed for expression screening and takes only a few minutes to carry out. Just as for conventional expression microarrays, the dual-color hybridization approach yields robust data if replicate experiments are performed, with the PCR products printed multiple times in each experiment. One major advantage of this method is that the cost is very competitive. Two pairs of universal labeled oligonucleotides can be used for genotyping any one SNP locus in thousands of individuals.
In summary, our experiments successfully demonstrated that the microarray-based method with layer-bylayer dual-color hybridization could be applied as an inexpensive and high-throughput tool for SNP genotyping in a large number of individuals. 
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• Confidence limits for quantified values (calibrators, control samples, or unknown samples) are calculated as the concentrations corresponding to the limits of the 95% confidence interval for the mean response for each replicate group, using the pooled standard deviation and the t-statistic based on the degrees of freedom for the pooled standard deviation.
To challenge the calculation system, we prepared a simulation using both a nonlinear calibration curve, based on the law of mass action, and a nonuniform response variance. The variance model contained a constant variance component and a proportional variance component:
Using this model, we simulated data from gaussian distributions as sets of four replicates for six calibrators, with the indicated means and standard deviations. The precision profile calculated from the simulated data is shown in Fig. 1 . A square-root response transformation produced the best variance uniformity (maximum P value for Bartlett's test), and the profile is based on the pooled standard deviation after response transformation.
In Table 1 , the calculated values for limit of detection, upper and lower limits of quantification (at 10% CV), and estimated calibrator concentrations are compared with the modeled values underlying the simulation. In all cases the 95% confidence intervals include the modeled values.
In conclusion, a new method has been developed for calculating precision profiles with use of the smaller data sets typically used in prototype assay characterization and optimization. Useful estimates of precision profiles and limits of detection and quantification can be obtained from a duplicate calibration curve, although triplicate or quadruplicate data substantially improve the confidence intervals.
The method is based on established techniques for estimating and handling response variation in the DOE setting: pooling the standard deviation, testing for variance uniformity, and response transformation when needed. The validity of the approach of response transformation was demonstrated by use of simulated data; all estimated parameters matched the underlying model within the 95% confidence intervals.
One novel feature of this method is that confidence intervals are calculated for reported parameters, providing protection against overinterpretation of results from small data sets. This approach makes efficient use of data from calibrators (and controls or unknowns, if present). The ability to generate full method characterization from small data sets should facilitate method optimization and development.
Software implementing this approach is available for free evaluation at www.ProQuant.com. 
